Transarterial Radioembolization and Immunotherapy: A Promising Combination for the Treatment of Hepatocellular Carcinoma

Monday, April 13, 2026

5:03 PM - 5:09 PM ET

Location: 714A

Abstract Presenter(s)

Rain Miller

Medical Student
The University of Toledo College of Medicine, United States

Author/Co-author(s)

SJ

Samir Jambhekar, MD, BS

Resident Physician
The Ohio State University Wexner Medical Center, United States
Mina S. Makary, MD (he/him/his)

Interventional Radiologist
The Ohio State University Wexner Medical Center, United States

Learning Objectives: (1) To review the current evidence surrounding the efficacy of transarterial chemoembolization (TARE) by itself, (2) and combined with immunotherapy for the treatment of hepatocellular carcinoma (HCC).

Background: Immunotherapy-based regimens have become a cornerstone of treatment for HCC, particularly in patients with unresectable disease and preserved hepatic function{1}. TARE has emerged as a leading minimally invasive treatment modality for intermediate-stage HCC. Multiple recent studies support the combined efficacy of TARE and immunotherapy for the treatment of HCC {2, 3, 4}. These studies examine different endpoints related to survival and quality of life. Understanding the outcomes of these studies can help interventionalists and partnering physicians tailor a treatment strategy specific to patients' individual treatment goals.

Clinical Findings/Procedure Details: Topics covered in this exhibit include 1) the present role of TARE compared to alternative interventional modalities in treating HCC, 2) notable recent studies regarding standalone TARE and immunotherapy for HCC treatment, 3) studies with both modalities combined, and 4) potential future applications of TARE and immunotherapy combinations.

Conclusion and/or Teaching Points: TARE has emerged as an established locoregional therapy for HCC. Multiple recent early-stage studies support the combined efficacy of TARE and immunotherapy for the treatment of HCC. These studies examine different endpoints related to survival and quality of life. Understanding the outcomes of these studies can help interventionalists and partnering physicians tailor a treatment strategy specific to patients' individual treatment goals.